Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has today announced that, in only four weeks and well ahead of schedule, it has successfully generated multiple Affimer reagents that bind the SARS-COV-2
In this video presentation, Avacta’s Chief Executive Officer Alastair Smith describes how a lateral flow rapid test works. Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology
Avacta Chief Executive Officer Alastair Smith was today interviewed on Sky News about our COVID-19 rapid test that is currently being developed. Avacta Group Plc (LON:AVCT) offers reagents and therapeutics
Alastair Smith provides overview of the COVID-19 collaboration with Cytiva. Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United
Avacta Group plc (LON:AVCT) CEO Alastair Smith joins DirectorsTalk to discuss the development and manufacture of a rapid test for the COVID-19 coronavirus infection for population screening. Alastair explains what the
World Bispecific is the Only End-to-End Conference Committed Solely to Advancing the Development of Bispecific Therapeutics Returning to Boston for the eleventh year, the World Bispecific Summit will deliver a greater scope
Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, today announced that it has entered into a collaboration with Cytiva, formerly known as GE Healthcare Life Sciences. The companies will develop
Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and research reagents, today announced that further to the announcement of 2 April 2020 detailing the subscription, and in response to substantial institutional
Avacta’s proprietary pre|CISION™ technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein (FAPα) which is highly upregulated in the tumour microenvironment of most solid tumours compared with
Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and research reagents, has today announced a proposed Subscription to raise gross proceeds of £2 million. The Subscription comprises of 11,111,110 subscription shares
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
